Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized,...

Area of Science:

• Gastroenterology
• Pharmacology
• Clinical Medicine

Background:

• Ulcerative colitis (UC) is characterized by high relapse rates.
• Investigating novel therapeutic strategies is crucial for managing active mild-to-moderate UC.
• Combined diosmectite and mesalazine efficacy was explored.

Purpose of the Study:

• To evaluate the efficacy of combined diosmectite and mesalazine in treating active mild-to-moderate UC.
• To assess clinical remission and mucosal healing rates during induction and maintenance phases.
• To compare outcomes against a placebo in a randomized controlled trial.

Main Methods:

• A randomized, single-blind, placebo-controlled study involving 120 UC patients.
• Patients were assigned to either a diosmectite (diosmectite and mesalazine) or placebo (placebo and mesalazine) group.
• Primary endpoints included clinical remission at 8 and 52 weeks; secondary endpoints assessed response, healing, symptom scores, and inflammatory markers.

Main Results:

• The diosmectite group showed significantly higher clinical remission (68.3% vs. 50% at 8 weeks; 61.7% vs. 40% at 52 weeks) and mucosal healing rates (66.7% vs. 48.3% at 8 weeks; 60% vs. 38.3% at 52 weeks) compared to placebo.
• No significant differences were observed in clinical response, Mayo score, or inflammatory markers between groups.
• A trend towards lower defecation frequency was noted in the diosmectite group, though not statistically significant.

Conclusions:

• Combined diosmectite and mesalazine treatment is effective in inducing and maintaining remission in active mild-to-moderate UC.
• The treatment demonstrates significant benefits in achieving clinical remission and promoting mucosal healing.
• This combination therapy represents a viable option for patients with active mild-to-moderate ulcerative colitis.